A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)

Mass Balance, Pharmacokinetics and Metabolism of [14C]BMS-582664 Prodrug of BMS-540215, in Subjects With Advanced or Metastatic Solid Tumors

The purpose of this trial is to determine the mass balance, pharmacokinetics, metabolism, and routes and extent of elimination of BMS-582664

Inclusion Criteria:

• Histologic/cytologic diagnosis of advanced or metastatic solid tumors
• ECOG 0-2
• 4/6 weeks since prior therapy

Exclusion Criteria:

• Brain metastases
• Secondary primary malignancy
• Thromboembolic disease requiring full anticoagulation within 6 months
• Inability to swallow or absorb oral therapy
• Uncontrolled hypertension